Paper
0
Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis
Authors
Shaji Kumar,Sundar Jagannath
Katja Weisel,Laura Dachs,Meletios Dimopoulos,David Siegel,Jorge Monge,Xavier Leleu,Juan Du,Javier Rubia,Jae Lee,María‐Victoria Mateos,Borja Martínez,Alessandro Gozzetti,Dominik Dytfeld,Enrique Ocio,Joan Bladé,Shuji Ozaki,Meral Beksaç,Fernando Escalante,Madhu Nagaraj,Rafla Hassan,Paul Spin,Nicolle Bonar,Mostafa Shokoohi,Muhaimen Siddiqui,Di Wang,Kevin Hou,J. Green,Olivier Humblet,Alexander Breskin,James Harnett,Wenzhen Ge,Rachel Sobel,Jessica Jalbert,Glenn Kroog,Karen Lorenc,Qiufei Ma,Christian Hampp
+37 authors
,Brian DurieJournal
Published
Nov 5, 2024
Show more
Save
Tip0
TipSave